Diane OK means return to French market, as OC safety review continues
This article was originally published in Scrip
Now that the European Commission has confirmed that Bayer's acne product, Diane (cyproterone acetate plus ethinylestradiol), should remain on the market but under strict prescribing conditions, attention will be turning to the fate of the combined hormonal contraceptives, which are also under scrutiny for their potential to cause thrombotic events.
You may also be interested in...
Pharmaceutical companies in the UK have again been asked to ensure they have contingency measures in place to deal with potential supply problems at channel ports – this time in preparation for the UK’s formal departure from the EU’s single market and customs union at the beginning of 2021. The industry is continuing to push for a mutual recognition agreement on drug regulation.
The UK BioIndustry Association has welcomed the government’s fresh investment in COVID-19 vaccine manufacturing capacity, while Sanofi and GSK are striking European and US deals for their vaccine candidate. A number of potential therapies are also being developed, including products based on interferon and hyperimmune globulin, but Roche/Chugai’s Actemra (tocilizumab) looks like a non-runner.
A parliamentary committee has come up with some ideas for strengthening the UK’s response to future demand surges due to the spread of COVID-19.